Form D · Biotechnology
QSAM Biosciences, Inc.
Austin, TX · CIK 0001310527
Offering snapshot reported Oct 6, 2022 · SEC filing
- Reported sold
- $925K Offering amount: $3.5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 6, 2022 | Initial | $925,000 | No comparison | 3 | SEC filing |
| Nov 15, 2021 | Initial | $555,000 | No comparison | 6 | SEC filing |
| Feb 5, 2021 | Initial | $2,500,000 | No comparison | 29 | SEC filing |
| Apr 10, 2017 | Initial | $1,000,000 | No comparison | 20 | SEC filing |
| Dec 11, 2015 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Dec 7, 2015 | Initial | $7,200,000 | No comparison | 83 | SEC filing |
| Jul 3, 2014 | Initial | $435,750 | No comparison | 1 | SEC filing |
| Jul 3, 2013 | Initial | $25,000 | No comparison | 1 | SEC filing |
| May 22, 2013 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Dec 22, 2009 | Initial | $495,000 | No comparison | 8 | SEC filing |
| Jul 9, 2009 | Amendment | $891,789 | $354,480vs Apr 22, 2009 | 29 | SEC filing |
| Apr 22, 2009 | Initial | $537,309 | No comparison | Not reported | SEC filing |
| Jul 9, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 25, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 18, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 15, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-461061
Board may increase offering size in its discretion beyond $3,500,000.
Source: Form D, filed Oct 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Baum | Director, Executive |
| Kevin Bolin | Director, Executive |
| J. Lloyd Breedlove | Executive |
| J Lloyd Breedlove | Director, Executive |
| Stephen J. Hoelscher | Executive |
| Adam King | Executive |
| Charles J. Link Jr. | Director |
| Joel Mayersohn | Director |
| Michelle Murcia | Executive |
| Christopher M Nelson | Executive |
| C. Richard Piazza | Director, Executive |
| Richard C Piazza | Director |
| Sudheer Pimputkar | Executive |
| William Jay Robbins | Director |
| Adriann Sax | Director |
| Christopher J. Spencer | Director |
| Scott Whitney | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9442 Capital Of Texas Hwy N Plaza 1 Suite 500
Austin, TX, 78759
Austin, TX, 78759